clinical trial · NCT07361510
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Bristol-Myers Squibb·phase3·recruiting·n = 750
Non-Small Cell Lung Cancer (NSCLC)PumitamigPembrolizumab
brief summary
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
started
Mar 12, 2026
primary completion
Oct 14, 2031
completion
Oct 14, 2031
last updated
Apr 15, 2026
official title
ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥ 50%.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol